Added value of the albumin-bilirubin score in predicting liver-related complications and mortality in metabolic-associated steatotic liver disease

doi:10.3748/wjg.v31.i37.110829

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 37

This Article

(59)

(51)

(0)

(1061)

(6)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Oct 7, 2025; 31(37): 110829
Published online Oct 7, 2025. doi: 10.3748/wjg.v31.i37.110829

Table 1 Baseline characteristics of metabolic-associated steatotic liver disease participants, n (%)

Characteristics	Total (n = 1163)	8-year liver-related complications			8-year all-cause mortality
Characteristics	Total (n = 1163)	Yes (n = 100)	No (n = 1063)	P value¹	Yes (n = 86)	No (n = 1077)	P value¹
Age (years), median IQR	56.0 (46.0 to 63.0)	61.5 (52.0 to 68.0)	55.0 (45.0 to 63.0)	< 0.001^a	62.0 (54.0 to 70.0)	55.0 (45.0 to 63.0)	< 0.001^a
Male	587 (50.5)	50 (50.0)	537 (50.5)	0.921	52 (60.5)	535 (49.7)	0.054
BMI (kg/m²), median IQR	26.4 (24.0 to 29.3)	27.6 (24.8 to 31.2)	26.3 (23.9 to 29.2)	0.034^a	25.8 (23.1 to 27.7)	26.4 (24.0 to 29.4)	0.038^a
Overweight/obesity	957 (82.3)	83 (83.0)	874 (82.2)	0.845	61 (70.9)	896 (83.2)	0.004^a
Hypertension	658 (57.8)	66 (68.0)	592 (56.9)	0.033^a	50 (62.5)	608 (57.5)	0.379
Prediabetes/diabetes	809 (81.6)	81 (88.0)	728 (81.0)	0.096	65 (86.7)	744 (81.2)	0.242
Hypertriglyceridemia	310 (29.9)	33 (36.3)	277 (29.3)	0.165	21 (28.0)	289 (30.0)	0.710
Low HDL	312 (30.3)	35 (38.0)	277 (29.5)	0.090	25 (34.3)	287 (30.0)	0.445
AST, median IQR	30.0 (23.0 to 40.0)	35.0 (24.0 to 57.0)	29.0 (23.0 to 39.0)	0.003^a	43.0 (25.0 to 65.0)	29.0 (23.0 to 39.0)	< 0.001^a
ALT, median IQR	33.0 (20.0 to 51.0)	36.5 (21.5 to 54.0)	33.0 (20.0 to 50.0)	0.390	36.0 (22.0 to 55.0)	33.0 (20.0 to 51.0)	0.358
Albumin (g/dL), median IQR	4.2 (4.0 to 4.5)	3.9 (3.6 to 4.2)	4.3 (4.0 to 4.5)	< 0.001^a	3.6 (2.8 to 4.1)	4.3 (4.0 to 4.5)	< 0.001^a
CAP (dB/m), median IQR	298.0 (275.0 to 329.0)	299.0 (278.5 to 325.0)	298.0 (275.0 to 330.0)	0.866	290.0 (271.0 to 312.0)	299.0 (275.0 to 331.0)	0.012^a
Steatosis grade				0.418			0.030^a
S1	383 (32.9)	28 (28.0)	355 (33.4)		36 (41.9)	347 (32.2)
S2	359 (30.9)	36 (36.0)	323 (30.4)		30 (34.9)	329 (30.6)
S3	421 (36.2)	36 (36.0)	385 (36.2)		20 (23.2)	401 (37.2)
LSM (kPa), median IQR	6.9 (5.2 to 11.6)	8.5 (6.1 to 14.9)	6.8 (5.1 to 11.0)	< 0.001^a	11.2 (7.6 to 32.5)	6.8 (5.1 to 10.7)	< 0.001^a
Fibrosis stage				0.035^a			< 0.001^a
F0	514 (44.2)	30 (30.0)	484 (45.5)		18 (20.9)	496 (46.0)
F1	127 (10.9)	11 (11.0)	116 (10.9)		4 (4.7)	123 (11.4)
F2	146 (12.5)	15 (15.0)	131 (12.3)		13 (15.1)	133 (12.4)
F3	138 (11.9)	15 (15.0)	123 (11.6)		13 (15.1)	125 (11.6)
F4	238 (20.5)	29 (29.0)	209 (19.7)		38 (44.2)	200 (18.6)
FIB-4, median IQR	1.3 (0.8 to 2.0)	1.7 (1.1 to 3.6)	1.2 (0.8 to 1.9)	< 0.001^a	2.1 (1.3 to 4.9)	1.2 (0.8 to 1.9)	< 0.001^a
ALBI, median IQR	-3.0 (-3.2 to -2.7)	-2.7 (-2.9 to -2.3)	-3.0 (-3.2 to -2.7)	< 0.001^a	-2.5 (-2.9 to -1.5)	-3.0 (-3.2 to -2.8)	< 0.001^a
ALBI grade				< 0.001^a			< 0.001^a
1	964 (82.9)	61 (61.0)	903 (85.0)		34 (39.5)	930 (86.3)
2	178 (15.3)	28 (28.0)	150 (14.1)		33 (38.4)	145 (13.5)
3	21 (1.8)	11 (11.0)	10 (0.9)		19 (22.1)	2 (0.2)
Advanced fibrosis group	261 (22.4)	35 (35.0)	226 (21.3)	0.002^a	43 (50.0)	218 (20.2)	< 0.001^a
Hepatitis B/C	358 (37.8)	24 (25.5)	334 (39.2)	0.010^a	39 (53.4)	319 (36.5)	0.004^a
Follow-up duration (years), median IQR	4.8 (2.5 to 6.3)	4.9 (2.5 to 6.5)	4.8 (2.5 to 6.3)	0.668	3.1 (1.8 to 5.0)	4.9 (2.6 to 6.4)	< 0.001^a

^aP < 0.05.

¹P value by Pearson’s χ² test or Mann-Whitney U test.

IQR: Interquartile range; BMI: Body mass index; HDL: High-density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CAP: Controlled attenuation parameter; LSM: Liver stiffness measurement; ALBI: Albumin-Bilirubin; FIB-4: Fibrosis-4.

Full Size Table

Citation: Sethasine S, Teerawongsakul P, Ruamtawee W, Treerasoradaj N, Navadurong H. Added value of the albumin-bilirubin score in predicting liver-related complications and mortality in metabolic-associated steatotic liver disease. World J Gastroenterol 2025; 31(37): 110829
URL: https://www.wjgnet.com/1007-9327/full/v31/i37/110829.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i37.110829

Sethasine S, Teerawongsakul P, Ruamtawee W, Treerasoradaj N, Navadurong H. Added value of the albumin-bilirubin score in predicting liver-related complications and mortality in metabolic-associated steatotic liver disease. World J Gastroenterol 2025; 31(37): 110829 [PMID: 41025016 DOI: 10.3748/wjg.v31.i37.110829]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.